Clinical trial · Observational
Study on the Role of FDG-PET in Patients With FL at Time of Relapse/Progression
Study on the Role of FDG-PET in Patients With Follicular Lymphoma at Time of Relapse/Progression
NCT03525665CI-TRIAL-00043230completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The study is designed as a retrospective analysis of patients with relapsed/refractory FL identified by the hematological centers of Italy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Follicular Lymphoma | Follicular Lymphoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Metabolic activity measured by FDG-PET | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- PFS
- timeFrame
- 24 months
- description
- Progression free survival from time of relapse/progression
Secondary outcomes (1)
- measure
- OS
- timeFrame
- 24 months
- description
- Overall survival
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with initial diagnosis of follicular lymphoma since 2001 * Histological confirmation of follicular lymphoma, grade I, II, III according to WHO 2008 classification, at the time of initial diagnosis * Systemic first-line treatment with immuno-chemotherapy * PET availability at the time of response after first-line treatment (optional) * Clinical and radiological evidence of FL relapse or progression * Histological confirmation of relapse (strongly recommended) * PET availability of at the time of relapse/progression and images available for central assessment * Availability of clinical, laboratory and therapeutic treatment data at the time of initial diagnosis and relapse/progression * Follow up of at least 12 months after relapse/progression Exclusion Criteria: * None
References
Publications (0)
Data not yet available
No reference posted for this study.